The study verified the safe completion of TDR in ASCs with good clinical and patient-reported outcomes, when compared to anterior cervical discectomy and fusion procedures and previous two-year TDR studies.
Here are five observations:
1. Malden, Mass.-based AxioMed’s President Jake Lubinski reacted to the study by observing that cervical TDR is “becoming a standard outpatient procedure, and AxioMed is leading the way with the most advanced disc replacement on the market.”
2. Mr. Lubinski’s believes many surgeons will use the AxioMed viscoelastic disc for outpatient surgeries, including multilevel surgeries. Kingsley Chin, MD, performed the first viscoelastic four-level cervical procedure at Andrews Memorial Hospital in Kingston, Jamaica, on Jan. 30, 2017.
3. The company has already conducted a preclinical European study, and Mr. Lubinski said they are now shifting focus to beginning a U.S. Investigational Device Exemption study for the multilevel cervical application.
4. The AxioMed viscoelastic disc is designed to restore natural disc alignment and motion.
5. Malden, Mass.-based KICVentures acquired AxioMed in 2014, but AxioMed still owns an exclusive viscoelastic material license on the disc’s technology.
More articles on devices:
North America leads global neurosurgery market — 5 observations
Corin Group to distribute FX Solution’s Reverse Shoulder System in U.S.
PEEK-OPTIMA™ HA Enhanced Devices — Drs. Timothy Bassett & Brad Prybis share early clinical experience
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
